Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?
About Anthem Biosciences
Anthem Biosciences' financial performance
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
The shares of the newly listed Anthem Biosciences rallied 3.3% on the BSE to their intraday high of Rs 746.70 in Monday's trade, after listing at a healthy premium of 27% over its IPO price.Meanwhile, the IPO investors are already sitting on an overall gain of 31%.Anthem Biosciences made a strong debut on the stock market with a listing gain of approximately 26.84% over its issue price of Rs 570, getting listed at around Rs 723. The IPO garnered massive investor interest, achieving an impressive overall subscription of 67.42 times, reflecting high demand across all categories.Anthem's issue had no fresh component, and the proceeds will go entirely to selling shareholders. Anchor investors had already pumped in Rs 1,016 crore before the IPO opening.After a bumper listing on the bourses, should you buy the shares of Anthem Biosciences?Shivani Nyati, Head of Wealth at Swastika Investmart , advises investors to secure partial profits and retain the remainder with a stop-loss set at Rs 650.'The company is one of the leading global players in the innovation-driven, technology-focused CRDMO segment . It enjoys a niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods,' noted Nyati.Additionally, Prashanth Tapse, Senior VP (Research) at Mehta Equities, highlighted, 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility,' while recommending a 'hold' rating on the stock.'Looking at its all financial as well as sectorial, we recommend investors to 'HOLD' the Anthem Biosciences for a long-term perspective. For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing,' he added.In the short term, he foresees Rs 900 as the target, while the long-term investors can hold it for Rs 1,000 and above.For the non-allottees, it is advised to wait for some volatility to settle in price and in case, if the stock is available around Rs 650-680, it can be considered as a good range to accumulate with long-term vision.Founded in 2006, Anthem operates across the drug development lifecycle—discovery, development, and commercial manufacturing—for both small molecules and biologics.With 196 projects underway, a global customer base across 44 countries, and a growing portfolio of fermentation-based APIs and specialty ingredients, the company has carved a niche in India's pharma value chain.In FY25, Anthem reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore. EBITDA came in at Rs 684 crore with a strong margin of nearly 37%, while debt levels remained low.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
24 minutes ago
- Indian Express
UK deal ‘gold standard' for FTAs; will retaliate if UK CBAM hurts India's interest: Commerce Minister Piyush Goyal
Commerce and Industry Minister Piyush Goyal on Saturday said the India-UK trade deal can serve as a gold standard for India's trade negotiations with other partners, as it opens India's doors for business while protecting sensitive sectors. He added that India will retaliate if the UK's carbon tax, set to come into effect on January 1, 2027, harms India's interests. 'Our effort is that the Indian industry gets preferential access over our competition, and I think this [UK FTA] can become a gold standard to ensure that India protects its sensitive sectors and opens the doors, particularly in highly labour-intensive sectors, and allows high-quality goods, technology and other products to come to India,' the minister said at a press briefing here. Goyal said most of India's free trade agreements (FTAs) are with countries that do not compete with India on anything, and that under the deal, the UK will be sending products which are in short supply in India. 'In every respect, this is an agreement which opens far greater opportunities for India than any other agreement,' the minister said. On concerns that the UK's Carbon Border Adjustment Mechanism (CBAM) could negate the tariff concessions India has received under the trade deal, Goyal said: 'Currently there is no CBAM in effect. So it cannot be addressed in the FTA. But India is a sovereign country, and if our export interests are hurt, we will react and retaliate, or 'rebalance'. I can assure everyone that no unilateral measure will go away without a proportionate response,' he said. 'There is a lot of opposition to CBAM in the EU as well, as the EU's cost of manufacturing and housing will become costlier, and so the sufferer will be the industry in the EU,' Goyal reiterated. A government official had said that India and the UK have arrived at a diplomatic understanding on CBAM, and that India will 'rebalance' the negative effect of CBAM by taking countermeasures. It has communicated its concern over CBAM in a 'note verbale'. However, the rebalancing measure is not part of the legal text, which has raised concerns over India's ability to address the CBAM issue legally. The Indian Express had reported on May 6 that CBAM was a major point of contention between the two countries and had been holding up the agreement. India had proposed a 'rebalancing mechanism' provision within the deal which would require the UK to compensate Indian industry for losses incurred due to the regulation. The paper reported that the 'rebalancing mechanism' article had been inserted into the 'general exceptions' chapter of the negotiating text between the two countries. This would have enabled India to claim compensation for its losses and ensure the UK does not raise a dispute against India at the World Trade Organisation (WTO). However, the UK likely did not agree to the same. Goyal said India and the UK plan to address the issue of critical minerals together, stating that 'concentration of certain supply chains in certain geographies' is a common problem, and both countries plan to work jointly on this. The India-UK Vision 2035, a document outlining the broader collaborative goals of the free trade agreement between the two, stated that both countries will work together to develop cutting-edge technology and research, building on the Technology Security Initiative. This will focus on future telecoms, artificial intelligence and critical minerals, laying the ground for future collaboration on semiconductors, quantum, biotechnology and advanced materials. To further cooperation in critical minerals, the two countries will also establish a UK-India Critical Minerals Guild to 'transform financing standards and innovation', according to a joint statement by the two. India has protected all sensitive sectors, including dairy, rice and sugar, in the free trade agreement with the UK, Commerce and Industry Minister Piyush Goyal said on Saturday. The pact will help boost exports of labour-intensive products like footwear, textiles, and gems and jewellery, he added. 'We have protected all the sensitive sectors of India… we have not opened those areas for the UK… Zero compromise and extensive benefits make it a phenomenal free trade agreement (FTA),' Goyal said. Ravi Dutta Mishra is a Principal Correspondent with The Indian Express, covering policy issues related to trade, commerce, and banking. He has over five years of experience and has previously worked with Mint, CNBC-TV18, and other news outlets. ... Read More
Deccan Herald
24 minutes ago
- Deccan Herald
Air India plane crash: Kin of 166 victims receive compensation
Over a month ago, Air India started releasing interim payments of Rs 25 lakh to the affected families, to help them meet their immediate financial needs.
Mint
24 minutes ago
- Mint
Nuvama sees 40% upside in THIS multibagger stock. Should you buy?
Multibagger stock: Brokerage firm Nuvama has initiated coverage on AGI Infra with a 'buy' recommendation due to ongoing and upcoming projects, anticipated high cash flows, and increasing demand for residential property. Shares of the construction company closed 1.29 per cent higher at ₹ 1,066.9 on the BSE index after Friday's stock market session, compared to ₹ 1.053.35 at the previous market close. 'We initiate coverage with a 'BUY' rating and a TP of INR1,448, valuing the stock at 1x FY26E NAV. AGI Infra (AGIIL) is among the few reputed real estate players in Punjab, with a dominant presence in Jalandhar, aided by a strong track record of well-received, high-quality projects,' Nuvama said. Operating in a market with limited branded competition, it has built a presence and is expanding into high-demand markets throughout Punjab. With a solid project pipeline and a large, well-situated land bank, it is estimated to benefit from Punjab's rising housing demand, according to the brokerage firm. Nuvama further expects that the ongoing and upcoming residential projects will generate a gross cash flow of ₹ 8,282 crore and a net cash flow of ₹ 2,060 crore. It has been recommended to buy with a target price of ₹ 1,448, an upside of 36%. AGIIL is a Punjab-based real estate developer with presence in cities such as Jalandhar, Ludhiana, Chandigarh, and Mohali. It has delivered over 10 projects. Primarily focused on residential real estate, it is also engaged in the commercial sector. Currently, it has 10 ongoing projects with a total saleable area of 11.32 million square feet, of which 4.98 million square feet remains available for sale. For the financial year ended on March 31, 2025, the company reported a net profit of ₹ 67 crore, compared to ₹ 52 crore posted in the previous year. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
